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The purpose of this study is to clarify absorption characteristics of a drug across 
the mesenteric surface which occupies a large area of absorption in the peritoneal 
cavity in order to determine the drug absorption route after intraperitoneal 
administration.   Absorption of phenolsulfonphthalein (PSP) as a model after 
application to the mesenteric surface was investigated in rats, by employing a 
cylindrical diffusion cell attached to the mesentery with or without blood vessels.   
PSP was absorbed from the rat mesenteric surface, followed by its appearance in 
the plasma and bile, regardless of blood vessel existence.   The absorption ratios 
of PSP in 6 h were calculated to be 92.1 % and 83.6 % from the mesenteric 
surface with and without blood vessels, respectively.   We then employed an 
experimental system by sticking a polyethylene cap (PE cap) on the surface of the 
other side to exclude the influence of absorption of the drug from the other organ 
surfaces that penetrated across the mesentery.   The PE cap-sticking decreased 
the appearance of PSP in the plasma from the mesenteric surface with blood 
vessels and eliminated the PSP absorption completely from the mesenteric surface 
without blood vessels.   Accordingly, blood vessels on the mesenteric surface 
actually play an important role in drug absorption, but the contribution of the 
mesenteric surface to drug absorption from the peritoneal cavity is unlikely to be 
significant due to there being a small effective area of blood vessels. 
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Introduction 
The peritoneal cavity is a potential space for peritoneal dialysis as a long-term renal 
replacement therapy and intraperitoneal (i.p.) chemotherapy of cancer restricted to the 
peritoneal cavity (e.g. ovarian carcinoma).   The effects of molecular weight (Dedrick et al 
1978; Litterst et al 1982), charge (Lukas et al 1971) and injection volume (Barrett et al 1991; 
Bredberg et al 1994) on drug absorption after i.p. administration have been reported.   
Although the i.p. route of drugs has attracted attention, it has not been fully clarified whether 
drug absorption from the peritoneal cavity occurs through the specific organs.   We 
previously examined the absorption characteristics of several compounds from the liver 
surface (Nishida et al 1994, 1995a-b, 1996, 1997), kidney surface (Kawakami et al 2002; 
Nakamura et al 2003), serosal gastric surface (Mukai et al 1999; Nakamura et al 1999) and 
serosal caecal surface (Nishida et al 2002) in rats in a series of investigations. 
 In the peritoneal cavity, mesentery is well developed and likely plays an important role in 
peritoneal drug transport due to its large surface area.   The mesentery with blood vessels 
and lymph ducts is a fold of the peritoneum attaching the stomach, small intestine and other 
organs to the posterior wall of the abdomen.   The absorption mechanism from the 
mesenteric surface needs to be examined in order to estimate in-vivo absorption of a drug 
after i.p. administration in humans by extrapolating the animal data.   However, the 
contribution of the mesentery to peritoneal drug absorption still remains obscure. 
 In the present study, we investigated the absorption of the organic anion 
phenolsulfonphthalein as a model after its application to the rat mesenteric surface.   
Moreover, we examined the influence of blood vessel existence and blocks of peritoneal 




Materials and methods 
Chemicals 
Phenolsulfonphthalein (PSP) was purchased from Nacalai Tesque, Inc. (Kyoto, Japan).   All 
other chemicals were of reagent grade. 
In-vivo experiment 
All animal experiments in the present study conformed to the Guideline for Animal 
Experimentation in Nagasaki University. 
 Male Wistar rats (250-316 g) were housed in cages in an air-conditioned room and 
maintained on standard rat foods and water freely available.   The left femoral artery and 
common bile duct of the rats were anaesthetized with sodium pentobarbitone (50 mg kg-1, 
i.p.) and cannulated with polyethylene tubes.   A cylindrical diffusion cell (i.d. 6 mm, area 
0.28 cm2) was attached to the rat mesenteric surface with or without blood vessels by the 
adhesive chemical Aron Alpha (Sankyo Co. Ltd., Tokyo, Japan).   The in-vivo experiments 
were performed under closed cavity conditions except for the region where the diffusion cell 
was attached.   A schematic drawing outlining the in-vivo experiment is illustrated in Figure 
1.   To exclude the influence of drug absorption from the other organ surfaces after 
penetration across the mesentery in the peritoneal cavity, we employed an experimental 
system by sticking a polyethylene cap (PE cap) on the surface of the other side attached to a 
diffusion cell, as shown in Figure 1. 
 One mg of PSP was dissolved in 0.05 mL of isotonic phosphate buffer (pH 7.4) and 
added to the diffusion cell directly.   After application of PSP to the rat mesenteric surface, 
the plasma, bile, urine and solution remaining in the diffusion cell were sampled at specified 
times. 
Analytical methods 
The concentrations of PSP in the plasma, bile, urine and solution remaining in the diffusion 
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cell were determined as follows.   The concentration of free PSP was determined 
spectrophotometrically at 560 nm after dilution with 1 M NaOH.   The total concentration 
of free PSP and its metabolite was measured in the same manner after they were subjected to 
acid hydrolysis (2 M HCl at 100°C for 30 min) (Hart and Schanker 1966).   The 
concentration of PSP metabolite (glucuronic acid conjugate) was estimated from the 
difference between these values.   PSP metabolite could not be detected in the plasma.   
The accuracy of the PSP assay was guaranteed by correlation coefficient of calibration curve 
(r2 > 0.998) and the detection limit was 0.01 µg mL-1. 
Calculation of moment parameters 
The plasma concentration profile of free PSP and biliary excretion rate profiles of free PSP 
and its metabolite were analyzed based on the statistical moment theory.   Statistical 
moment theory has been used to calculate overall parameters to evaluate drug absorbability.   
Moment parameters for a plasma concentration profile of free PSP (AUCp, MRTp) and those 
for biliary excretion rate profiles of free PSP (AUCb,f, MRTb,f) and its metabolite (AUCb,m, 
MRTb,m) were calculated using a linear trapezoidal formula and extrapolation to infinite time 
based on a monoexponential equation (Yamaoka et al 1978). 
Statistical analysis 
Statistical analysis was performed by applying a 2-way ANOVA, followed by post hoc 
Tukey's test.   P < 0.05 was considered to be statistically significant.   All values were 
expressed as the mean value ± standard error (s.e.) of at least four experiments. 
 
 
Results and discussion 
We have established an experimental system utilizing a cylindrical diffusion cell attached to 
the rat mesenteric surface.   This experimental system enables us to examine drug 
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absorption from the mesenteric surface without interference by absorption from the other sites.   
We selected hydrophilic dye PSP as a model, because its absorption from several organ 
surfaces has been well characterized (Nishida et al 1994, 1995a-b, 1997, 2002; Nakamura et 
al 1999; Mukai et al 1999).   In addition, PSP disposition characteristics have been 
investigated previously (Enna and Schanker 1973; Nishida et al 1989; Kakutani et al 1992). 
Absorption of PSP across the mesenteric surface in rats 
The mesenteric vascular system is so developed that absorption from the blood vessel surface 
should be relatively good.   Therefore, we assessed drug absorption from the mesenteric 
surface with or without blood vessels, and attached a diffusion cell to each region of rat 
mesenteric surface as illustrated in Figure 1. 
 Figures 2A and 2B show the plasma concentration profile of free PSP after application to 
the rat mesenteric surface without or with blood vessels at a dose of 1 mg, respectively.   
The PSP that appeared in the plasma reached maximum 1 h after dosing, suggesting the 
occurrence of drug absorption from the rat mesenteric surface regardless of blood vessel 
existence.   After absorption from the rat mesenteric surface without or with blood vessels, 
free PSP was excreted into the bile as shown in Figures 3A and 3B.   The metabolite of PSP 
(glucuronic acid conjugate) was also excreted into the bile (Figures 3A and 3B).   The 
absorption ratios of PSP in 6 h calculated from the PSP amount remaining in the diffusion cell 
were not significantly different (92.1 % and 83.6 %, with and without blood vessels, 
respectively) (Table 1).   Accordingly, good absorption of PSP from the mesenteric surface 
was demonstrated, although PSP is poorly absorbed from the gastrointestinal mucosa because 
it is highly ionized and has a very small partition coefficient at physiological pH (Schanker et 
al 1958). 
Diffusion into the peritoneal cavity of PSP penetrated across the mesentery 
Rapid absorption of PSP was recognized (Figures 2A and 2B) regardless of blood vessel 
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existence on the mesenteric surface of the rats.   However, we observed the penetration of 
PSP through the mesentery in the case of attaching a diffusion cell on the rat mesentery in-
vitro (data not shown).   This implies the possibility that the administered PSP penetrates the 
mesentery, followed by absorption from the other organ surfaces in the peritoneal cavity.   
Therefore, the diffusion into the peritoneal cavity of PSP that penetrates through the 
mesenteric surface must be removed to evaluate precisely the absorption only from the 
mesenteric surface.   We employed an experimental system by sticking a PE cap on the 
surface of the other side of the mesentery attached to the diffusion cell to inhibit drug 
diffusion into the peritoneal cavity (Figure 1). 
 In the experiment using a PE cap for the mesenteric surface with blood vessels, the 
plasma concentrations of PSP decreased (Figure 2B).   On the other hand, the appearance of 
PSP in the plasma disappeared completely on account of the PE cap after application to the rat 
mesenteric surface without blood vessels (Figure 2A).   Similar tendencies were observed 
with the biliary excretion rate profiles of free PSP and its metabolite (Figures 3A and 3B).   
As listed in Table 1, the absorption ratios of PSP were high with or without blood vessels in 
the experiment attached with only a diffusion cell to the rat mesenteric surface.   However, 
the PE cap-sticking method significantly decreased the absorption ratio of PSP to 8.3 % (P < 
0.01) without blood vessels (Table 1).   In addition, the absorption ratio of PSP was 
decreased to 66.9 % with blood vessels, although the difference was not significant.   The 
biliary and urinary excretion of free PSP and its metabolite also decreased according to the 
reduction in absorption, and they were not detected after absorption from the mesenteric 
surface without blood vessels.   Accordingly, these results imply that most of the PSP that 
penetrated through the mesentery was absorbed from the other organ surfaces in the 
experimental system attached only to a diffusion cell.   Consequently, it appears that blood 
vessels on the mesentery surface actually play an important role in drug absorption, and that 
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contribution of the mesenteric surface to drug absorption from the peritoneal cavity is not 
marked because of the small effective area of blood vessels. 
 The overall absorption and excretion processes can be evaluated with moment parameters 
with regard to extent and rate.   Table 2 lists the moment parameters for the plasma 
concentration profiles of free PSP and biliary excretion rate profiles of free PSP and its 
metabolite.   A decrease was observed in the AUCp, AUCb,f, and AUCb,m by sticking the PE 
cap on the surface of the other side of the mesentery with blood vessels.   After application 
to the mesentery without blood vessel the MRTp (220.2 min) was longer than that of the blood 
vessels and PE cap (171.9 min), representing the time necessary for absorption from the other 
organ surfaces after penetration through the mesenteric surface (Table 2). 
 
 In conclusion, the mesenteric surface itself does not contribute to PSP absorption, and 
absorption could mostly result from the blood vessel on the mesenteric surface.   The 
present results should provide us useful information in determining the drug absorption across 
the mesentery. 
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Table 1  Recovery (% of dose) of PSP at 6 h after application to the rat mesenteric surface 
under several application conditions at a dose of 1 mg 
 
 Application Diffusion  Bile   Urine  
 –––––––––––––––––––––– –––––––––––––––––––––– 
 condition cell Total Free Metabolite Total Free Metabolite 
 
Mesentery without blood vessel 
  without 16.4 40.6 24.0 16.6 34.9 22.8 12.1 
  PE cap ±2.8 ±2.4 ±2.1 ±1.8 ±1.8 ±3.3 ±2.2 
  with 91.7 N.D. N.D. N.D. N.D. N.D. N.D. 
  PE cap ±0.5       
Mesentery with blood vessel 
  without 7.9 45.3 24.7 20.7 38.0 21.7 16.3 
  PE cap ±1.9 ±4.2 ±1.5 ±2.7 ±3.3 ±3.5 ±1.0 
  with 33.1 32.4 20.3 12.1 28.2 17.3 11.0 
  PE cap ±5.3 ±4.0 ±2.3 ±1.8 ±1.6 ±1.2 ±1.1 
 
Each value is mean ± s.e. of at least four experiments. 





Table 2  Moment parameters of PSP after application to the rat mesenteric surface under 
several application conditions at a dose of 1 mg 
 
 Application AUCp MRTp AUCb,f MRTb,f AUCb,m MRTb,m
 condition (µg min mL-1) (min) (µg) (min) (µg) (min) 
 
Mesentery without blood vessel 
  without 573.1 220.2 271.4 183.7 196.1 205.9 
  PE cap ±29.7 ±25.7 ±21.4 ±8.8 ±22.9 ±9.6 
  with N.C. N.C. N.C. N.C. N.C. N.C. 
  PE cap       
 
Mesentery with blood vessel 
  without 493.7 177.0 269.1 158.1 229.0 175.4 
  PE cap ±61.1 ±26.1 ±16.5 ±18.8 ±29.2 ±17.7 
  with 326.7 171.9 240.2 208.7 145.2 218.5 
  PE cap ±53.7 ±17.0 ±24.5 ±15.8 ±21.3 ±14.3 
 
N.C.: not calculated because of undetectable PSP concentrations in the plasma and bile. 




Figure 1  Experimental method for drug application to the rat mesenteric surface 
 A cylindrical diffusion cell made of glass (i.d. 6 mm, area 0.28 cm2) was employed to 
selectively study the absorption of a drug from the rat mesenteric surface.   The diffusion 
cell was attached to the rat mesenteric surface without or with blood vessels as illustrated by a 
dotted circle (A) and a circle (B), respectively, using Aron Alpha biocompatible glue in the 
hatched region.   In some experiments, a polyethylene cap (PE cap) was attached on the 
other side to block the diffusion of the drug absorbed across the mesenteric surface.   All 
dimensions are approximate. 
 
Figure 2  Plasma concentration profiles of free PSP after application to the rat mesenteric 
surface without (A) or with blood vessel (B) at a dose of 1 mg 
 Key: ●; Without PE cap  ○; With PE cap.   Each point represents the mean ± s.e. of 
at least four experiments. 
 
Figure 3  Biliary excretion rate profiles of free PSP and its metabolite after application to 
the rat mesenteric surface without (A) or with blood vessel (B) at a dose of 1 mg 
 Key: Without PE cap (free PSP ●, PSP metabolite ○), With PE cap (free PSP ▲, PSP 














































































0 120 240 360
(A) (B)
 
 
17 
